ALCYONE Update: Adding Daratumumab to VMP Improves Survival in Transplant-Ineligible Myeloma
In patients with newly diagnosed multiple myeloma (MM) who are ineligible for high-dose chemotherapy and transplantation, adding daratumumab to bortezomib, melphalan, and prednisone (VMP)...
Lenalidomide Treatment Delays Progression From Smoldering to Symptomatic Myeloma
Observation is the standard approach to managing most patients with smoldering multiple myeloma (MM), but results from a phase III study suggest that early...
Early Intensification of Intrathecal Chemotherapy Reduces Risk of Relapse in Pediatric ALL
Two additional doses of intrathecal therapy early during induction treatment for children with newly diagnosed acute lymphocytic leukemia (ALL) who were at increased risk...
Stephen Hahn Confirmed as FDA Commissioner, Beth Shaz Becomes AABB President, and more
Stephen Hahn Confirmed as FDA Commissioner
The U.S. Senate voted 72−18 to confirm Stephen Hahn, MD, as the FDA’s new commissioner. President Donald Trump nominated...
Acalabrutinib Approved for CLL Under New International Collaboration
The FDA granted a supplemental approval to acalabrutinib for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Acalabrutinib...
Shifting From Eligibility to Optimization of Transplant in Older Adults With Hematologic Malignancies
In an article published in Blood Advances, researchers from the University of Chicago reported efforts to optimize outcomes after hematopoietic cell transplantation (HCT) in...
Updates From ECHELON-1: Brentuximab Vedotin Provides Durable Efficacy in Hodgkin Lymphoma
Previously reported results from the phase III ECHELON-1 trial suggested that replacing bleomycin with brentuximab vedotin in the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)...
Achievement of MRD Negativity Predicts Favorable Prognosis in RUNX1-RUNX1T1+ AML
In patients with acute myeloid leukemia (AML) with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1+ fusion, serial assessment of measurable residual disease (MRD) can identify people at a high risk...
Bristol-Myers Wins $752 Million From Gilead in Patent Dispute
Bristol-Myers Squibb has won a $752 million lawsuit against Gilead Sciences to settle a U.S. patent dispute regarding the chimeric antigen receptor (CAR) T-cell...
FDA Approves Voxelotor for Sickle Cell Disease
The FDA has approved voxelotor, a once-daily oral therapy that modulates hemoglobin affinity for oxygen by binding to hemoglobin S and stabilizing it, to...
Current Issue
January 2020 Annual Meeting Edition
This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.
